Webster, H. H.
Nyberg, T. http://orcid.org/0000-0002-9436-0626
Sinnathamby, M. A.
Aziz, N. Abdul
Ferguson, N. http://orcid.org/0000-0002-1154-8093
Seghezzo, G. http://orcid.org/0000-0002-0540-5897
Blomquist, P. B.
Bridgen, J.
Chand, M.
Groves, N.
Myers, R.
Hope, R.
Ashano, E.
Lopez-Bernal, J. http://orcid.org/0000-0002-1301-5653
De Angelis, D.
Dabrera, G. http://orcid.org/0000-0003-4606-5945
Presanis, A. M.
Thelwall, S. http://orcid.org/0000-0002-0434-2724
Article History
Received: 9 June 2022
Accepted: 29 September 2022
First Online: 13 October 2022
Competing interests
: N.M.F. sits on a number of UK government and World Health Organization groups providing scientific advice relating to SARS-CoV-2. G.D. declares that his employer UK Health Security Agency (previously operating as Public Health England) received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID-19, and G.D. had no role in and received no funding from the project. D.D.A. sits on two UK government groups providing scientific advice relating to SARS-CoV-2 (Scientific Pandemic Influenza Group on Modelling [SPI-M] and UKHSA’s Variant Technical Group [VTG]). The remaining authors declare no competing interests.
: This surveillance was performed as part of the UK Health Security Agency’s (UKHSA) responsibility to monitor COVID-19 during the current pandemic. UKHSA has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to process confidential patient information under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(iii) as part of its outbreak response activities. This study falls within the research activities approved by the UKHSA Research Ethics and Governance Group.